329 related articles for article (PubMed ID: 33468477)
1. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.
Hoglund RM; Workman L; Edstein MD; Thanh NX; Quang NN; Zongo I; Ouedraogo JB; Borrmann S; Mwai L; Nsanzabana C; Price RN; Dahal P; Sambol NC; Parikh S; Nosten F; Ashley EA; Phyo AP; Lwin KM; McGready R; Day NP; Guerin PJ; White NJ; Barnes KI; Tarning J
PLoS Med; 2017 Jan; 14(1):e1002212. PubMed ID: 28072872
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
5. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.
Patel K; Batty KT; Moore BR; Gibbons PL; Kirkpatrick CM
J Antimicrob Chemother; 2014 Aug; 69(8):2155-63. PubMed ID: 24777899
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
7. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
8. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
9. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
[TBL] [Abstract][Full Text] [Related]
11. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
[TBL] [Abstract][Full Text] [Related]
12. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
Witkowski B; Duru V; Khim N; Ross LS; Saintpierre B; Beghain J; Chy S; Kim S; Ke S; Kloeung N; Eam R; Khean C; Ken M; Loch K; Bouillon A; Domergue A; Ma L; Bouchier C; Leang R; Huy R; Nuel G; Barale JC; Legrand E; Ringwald P; Fidock DA; Mercereau-Puijalon O; Ariey F; Ménard D
Lancet Infect Dis; 2017 Feb; 17(2):174-183. PubMed ID: 27818097
[TBL] [Abstract][Full Text] [Related]
13. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
Byakika-Kibwika P; Ssenyonga R; Lamorde M; Blessborn D; Tarning J
BMC Infect Dis; 2019 Dec; 19(1):1025. PubMed ID: 31795967
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
[TBL] [Abstract][Full Text] [Related]
15. A trial of combination antimalarial therapies in children from Papua New Guinea.
Karunajeewa HA; Mueller I; Senn M; Lin E; Law I; Gomorrai PS; Oa O; Griffin S; Kotab K; Suano P; Tarongka N; Ura A; Lautu D; Page-Sharp M; Wong R; Salman S; Siba P; Ilett KF; Davis TM
N Engl J Med; 2008 Dec; 359(24):2545-57. PubMed ID: 19064624
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.
Lohy Das JP; Kyaw MP; Nyunt MH; Chit K; Aye KH; Aye MM; Karlsson MO; Bergstrand M; Tarning J
Malar J; 2018 Mar; 17(1):126. PubMed ID: 29566683
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.
Manning J; Vanachayangkul P; Lon C; Spring M; So M; Sea D; Se Y; Somethy S; Phann ST; Chann S; Sriwichai S; Buathong N; Kuntawunginn W; Mitprasat M; Siripokasupkul R; Teja-Isavadharm P; Soh E; Timmermans A; Lanteri C; Kaewkungwal J; Auayporn M; Tang D; Chour CM; Prom S; Haigney M; Cantilena L; Saunders D
Antimicrob Agents Chemother; 2014 Oct; 58(10):6056-67. PubMed ID: 25092702
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.
Rovira-Vallbona E; Van Hong N; Kattenberg JH; Huan RM; Hien NTT; Ngoc NTH; Guetens P; Hieu NL; Mai TT; Duong NTT; Duong TT; Phuc BQ; Xa NX; Erhart A; Rosanas-Urgell A
J Antimicrob Chemother; 2020 Aug; 75(8):2272-2281. PubMed ID: 32437557
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
20. Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.
Pasay CJ; Rockett R; Sekuloski S; Griffin P; Marquart L; Peatey C; Wang CY; O'Rourke P; Elliott S; Baker M; Möhrle JJ; McCarthy JS
J Infect Dis; 2016 Jul; 214(1):105-13. PubMed ID: 27056954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
